{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:47:48Z","timestamp":1776235668870,"version":"3.50.1"},"reference-count":25,"publisher":"Portland Press Ltd.","issue":"3","license":[{"start":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T00:00:00Z","timestamp":1564012800000},"content-version":"vor","delay-in-days":3254,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,9,15]]},"abstract":"<jats:p>LRRK2 (leucine-rich repeat protein kinase 2) is mutated in a significant number of Parkinson's disease patients. Since a common mutation that replaces Gly2019 with a serine residue enhances kinase catalytic activity, small-molecule LRRK2 inhibitors might have utility in treating Parkinson's disease. However, the effectiveness of inhibitors is difficult to assess, as no physiological substrates or downstream effectors have been identified that could be exploited to develop a robust cell-based assay. We recently established that LRRK2 bound 14-3-3 protein isoforms via its phosphorylation of Ser910 and Ser935. In the present study we show that treatment of Swiss 3T3 cells or lymphoblastoid cells derived from control or a Parkinson's disease patient harbouring a homozygous LRRK2(G2019S) mutation with two structurally unrelated inhibitors of LRRK2 (H-1152 or sunitinib) induced dephosphorylation of endogenous LRRK2 at Ser910 and Ser935, thereby disrupting 14-3-3 interaction. Our results suggest that H-1152 and sunitinib induce dephosphorylation of Ser910 and Ser935 by inhibiting LRRK2 kinase activity, as these compounds failed to induce significant dephosphorylation of a drug-resistant LRRK2(A2016T) mutant. Moreover, consistent with the finding that non-14-3-3-binding mutants of LRRK2 accumulated within discrete cytoplasmic pools resembling inclusion bodies, we observed that H-1152 causes LRRK2 to accumulate within inclusion bodies. These findings indicate that dephosphorylation of Ser910\/Ser935, disruption of 14-3-3 binding and\/or monitoring LRRK2 cytoplasmic localization can be used as an assay to assess the relative activity of LRRK2 inhibitors in vivo. These results will aid the elaboration and evaluation of LRRK2 inhibitors. They will also stimulate further research to understand how phosphorylation of Ser910 and Ser935 is controlled by LRRK2, and establish any relationship to development of Parkinson's disease.<\/jats:p>","DOI":"10.1042\/bj20100784","type":"journal-article","created":{"date-parts":[[2010,7,23]],"date-time":"2010-07-23T05:57:41Z","timestamp":1279864661000},"page":"405-413","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":355,"title":["Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910\/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization"],"prefix":"10.1042","volume":"430","author":[{"given":"Nicolas","family":"Dzamko","sequence":"first","affiliation":[{"name":"MRC Protein Phosphorylation Unit, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, Scotland, U.K."}]},{"given":"Maria","family":"Deak","sequence":"additional","affiliation":[{"name":"MRC Protein Phosphorylation Unit, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, Scotland, U.K."}]},{"given":"Faycal","family":"Hentati","sequence":"additional","affiliation":[{"name":"Department of Neurology, Institut National de Neurologie, Tunis, Tunisia"}]},{"given":"Alastair\u00a0D.","family":"Reith","sequence":"additional","affiliation":[{"name":"External Alliances & Development, GlaxoSmithKline (China) R&D Co. Ltd, Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 ZNY U.K."}]},{"given":"Alan\u00a0R.","family":"Prescott","sequence":"additional","affiliation":[{"name":"Division of Cell Biology and Immunology, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, Scotland, U.K."}]},{"given":"Dario\u00a0R.","family":"Alessi","sequence":"additional","affiliation":[{"name":"MRC Protein Phosphorylation Unit, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, Scotland, U.K."}]},{"given":"R.\u00a0Jeremy","family":"Nichols","sequence":"additional","affiliation":[{"name":"MRC Protein Phosphorylation Unit, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, Scotland, U.K."}]}],"member":"288","published-online":{"date-parts":[[2010,8,27]]},"reference":[{"key":"2021112214430810700_B1","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.neuron.2004.11.005","article-title":"Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology","volume":"44","author":"Zimprich","year":"2004","journal-title":"Neuron"},{"key":"2021112214430810700_B2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.neuron.2004.10.023","article-title":"Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease","volume":"44","author":"Paisan-Ruiz","year":"2004","journal-title":"Neuron"},{"key":"2021112214430810700_B3","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1474-4422(08)70117-0","article-title":"Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study","volume":"7","author":"Healy","year":"2008","journal-title":"Lancet Neurol."},{"key":"2021112214430810700_B4","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbadis.2008.09.015","article-title":"Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease","volume":"1792","author":"Biskup","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"2021112214430810700_B5","doi-asserted-by":"crossref","DOI":"10.1042\/AN20090007","article-title":"Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions","volume":"1","author":"Greggio","year":"2009","journal-title":"ASN NEURO"},{"key":"2021112214430810700_B6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1042\/BJ20100483","article-title":"14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization","volume":"430","author":"Nichols","year":"2010","journal-title":"Biochem. J."},{"key":"2021112214430810700_B7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1042\/BJ20070209","article-title":"LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity","volume":"405","author":"Jaleel","year":"2007","journal-title":"Biochem. J."},{"key":"2021112214430810700_B8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1042\/BJ20091035","article-title":"Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease","volume":"424","author":"Nichols","year":"2009","journal-title":"Biochem. J."},{"key":"2021112214430810700_B9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.bbrc.2008.11.048","article-title":"Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2","volume":"378","author":"Covy","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021112214430810700_B10","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1742-4658.2008.06789.x","article-title":"Investigation of leucine-rich repeat kinase 2: enzymological properties and novel assays","volume":"276","author":"Anand","year":"2009","journal-title":"FEBS J."},{"key":"2021112214430810700_B11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.nbd.2006.04.001","article-title":"Kinase activity is required for the toxic effects of mutant LRRK2\/dardarin","volume":"23","author":"Greggio","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"2021112214430810700_B12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1021\/jm0609014","article-title":"Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors","volume":"50","author":"Goodman","year":"2007","journal-title":"J. Med. Chem."},{"key":"2021112214430810700_B13","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S1474-4422(08)70116-9","article-title":"LRRK2 Gly2019Ser penetrance in Arab\u2013Berber patients from Tunisia: a case-control genetic study","volume":"7","author":"Hulihan","year":"2008","journal-title":"Lancet Neurol."},{"key":"2021112214430810700_B14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jviromet.2006.07.024","article-title":"Transfection of mammalian cells using linear polyethylenimine is a simple and effective means of producing recombinant adeno-associated virus vectors","volume":"138","author":"Reed","year":"2006","journal-title":"J. Virol. Methods."},{"key":"2021112214430810700_B15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-313X.1999.00417.x","article-title":"Phosphorylation-dependent interactions between enzymes of plant metabolism and 14-3-3 proteins","volume":"18","author":"Moorhead","year":"1999","journal-title":"Plant J."},{"key":"2021112214430810700_B16","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1093\/hmg\/ddp346","article-title":"LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model","volume":"18","author":"Alegre-Abarrategui","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"2021112214430810700_B17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/BJ20070797","article-title":"The selectivity of protein kinase inhibitors: a further update","volume":"408","author":"Bain","year":"2007","journal-title":"Biochem. J."},{"key":"2021112214430810700_B18","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.bbrc.2009.08.163","article-title":"The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites","volume":"389","author":"Greggio","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021112214430810700_B19","doi-asserted-by":"crossref","first-page":"10963","DOI":"10.1021\/bi9011379","article-title":"Identification of the autophosphorylation sites of LRRK2","volume":"48","author":"Kamikawaji","year":"2009","journal-title":"Biochemistry"},{"key":"2021112214430810700_B20","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1021\/pr9008578","article-title":"Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2","volume":"9","author":"Gloeckner","year":"2010","journal-title":"J. Proteome Res."},{"key":"2021112214430810700_B21","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1021\/pr800599n","article-title":"Solid tumor proteome and phosphoproteome analysis by high resolution mass spectrometry","volume":"7","author":"Zanivan","year":"2008","journal-title":"J. Proteome Res."},{"key":"2021112214430810700_B22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0014-5793(94)80252-1","article-title":"The threonine residues in MAP kinase kinase 1 phosphorylated by MAP kinase in vitro are also phosphorylated in nerve growth factor-stimulated rat phaeochromocytoma (PC12) cells","volume":"341","author":"Saito","year":"1994","journal-title":"FEBS Lett."},{"key":"2021112214430810700_B23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/sj.onc.1201214","article-title":"EGF induced SOS phosphorylation in PC12 cells involves P90 RSK-2","volume":"15","author":"Douville","year":"1997","journal-title":"Oncogene"},{"key":"2021112214430810700_B24","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1083\/jcb.200403069","article-title":"The TSC1-2 tumor suppressor controls insulin\u2013PI3K signaling via regulation of IRS proteins","volume":"166","author":"Harrington","year":"2004","journal-title":"J. Cell Biol."},{"key":"2021112214430810700_B25","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1128\/MCB.00735-09","article-title":"Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1","volume":"29","author":"Dibble","year":"2009","journal-title":"Mol. Cell. Biol."}],"container-title":["Biochemical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/430\/3\/405\/664434\/bj4300405.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/430\/3\/405\/664434\/bj4300405.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T18:58:16Z","timestamp":1637607496000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemj\/article\/430\/3\/405\/45431\/Inhibition-of-LRRK2-kinase-activity-leads-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,27]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,9,15]]}},"URL":"https:\/\/doi.org\/10.1042\/bj20100784","relation":{},"ISSN":["0264-6021","1470-8728"],"issn-type":[{"value":"0264-6021","type":"print"},{"value":"1470-8728","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,27]]}}}